Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.0% |
| STEPHENS, AMELIA CAROLE | 1 | 80.0% | +50.0% |
| MCKOY, QUINCY ANDRE | 1 | 70.3% | +39.6% |
| BARSKY, JARED | 1 | 50.3% | +23.1% |
| HASTINGS, ALISON AZAR | 1 | 63.3% | +40.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | HASTINGS, ALISON AZAR | 6d |
| 18565163 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | STEPHENS, AMELIA CAROLE | — |
| 18485780 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | MCKOY, QUINCY ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | HASTINGS, ALISON AZAR | 6d |
| 18640909 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — |
| 18565163 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | STEPHENS, AMELIA CAROLE | — |
| 18485780 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | MCKOY, QUINCY ANDRE | — |
| 18485766 | ISOINDOLINONE COMPOUNDS | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18640909 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — | §112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18565163 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18485780 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | MCKOY, QUINCY ANDRE | 1626 | §102§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18485766 | ISOINDOLINONE COMPOUNDS | BARSKY, JARED | 1628 | §112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | HASTINGS, ALISON AZAR | 1627 | §102§103§112Other | Final Rejection | 6d | Pending | Sep 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial